BB Biotech says it had to weather the storm last year
BB Biotech managed to “weather the storm” that gripped the biotech sector in 2016 and beat its benchmark index, according to its latest annual report.
biotech
-
-
M&A deals will continue to boost biotech
At first glance, it seems large healthcare companies have lost interest in M&A. According to Dealogic, year-to-date deal volumes are 25% lower than for the same period last year.
-
Volatility presents opportunities in biotech – BB Biotech
The recent sell-off in global stock markets has presented attractive takeover opportunities in the biotech sector, according to BB Biotech AG.
-
AXA expands biotech and healthcare team
AXA Investment Managers hires Peter Hughes as a healthcare equity analyst to its biotech and healthcare team.
-
Contrarian view on US equities can reap rewards – Legg Mason
Taking a contrarian view on United States equities can reap rewards according to Evan Bauman, co-lead manager of the Legg Mason ClearBridge US Aggressive Growth Fund.